Education
About Us
Working with TipRanks
Follow Us
Stoke Therapeutics Inc (STOK)
NASDAQ:STOK
STOK Stock Chart & Stats
$30.97
-$0.34(-3.65%)
At close: 4:00 PM EST
$30.97
-$0.34(-3.65%)
Day’s Range― - ―
52-Week Range$5.35 - $38.69
Previous CloseN/A
Volume337.58K
Average Volume (3M)842.86K
Market Cap
$1.77B
Enterprise Value$1.13B
Total Cash (Recent Filing)$248.31M
Total Debt (Recent Filing)$2.91M
Price to Earnings (P/E)46.9
Beta1.60
Next Earnings
Mar 11, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding57,117,150
10 Day Avg. Volume801,055
30 Day Avg. Volume842,860
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.60
Price to Sales (P/S)16.30
P/FCF Ratio-6.84
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue5.51
Enterprise Value/Gross Profit5.54
Enterprise Value/Ebitda34.25
Forecast
1Y Price Target
$35.75Price Target Upside15.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.11
Revenue Forecast (FY)$25.61M
Bulls Say, Bears Say
Bulls Say
Evidence Of Disease-modifying BenefitConsistent non-seizure improvements across communication and adaptive behavior measures, backed by KOL validation and supportive Phase 1/2 data, strengthen the case for a broad, disease-modifying label and higher commercial value.
Regulatory Engagement And Expedited PathwayBreakthrough Therapy designation combined with planned FDA meetings and a rolling submission strategy increases the potential for expedited review or earlier access if regulators are receptive.
Trial Enrollment AccelerationPhase 3 EMPEROR enrollment progressing faster than expected reduces execution risk and shortens the path to a pivotal efficacy readout, supporting a quicker regulatory filing trajectory.
Bears Say
Regulatory Uncertainty On Key Efficacy AnalysesRegulators treating a key efficacy analysis as post hoc and requesting additional Vineland-3 analyses creates ambiguity around the evidence package and could prolong review timelines.
Risk Of Narrow ApprovalFiling based on limited early data risks an approval confined to seizure reduction rather than disease modification, which could weaken pricing power and limit market penetration.
Stock Volatility From Regulatory InteractionsDifferences with regulators on filing strategy have previously led to sharp share pullbacks, and upcoming regulatory interactions may produce renewed volatility around key decision points.
Stoke Therapeutics News
STOK FAQ
What was Stoke Therapeutics Inc’s price range in the past 12 months?
Stoke Therapeutics Inc lowest stock price was $5.35 and its highest was $38.69 in the past 12 months.
What is Stoke Therapeutics Inc’s market cap?
Stoke Therapeutics Inc’s market cap is $1.77B.
When is Stoke Therapeutics Inc’s upcoming earnings report date?
Stoke Therapeutics Inc’s upcoming earnings report date is Mar 11, 2026 which is in 54 days.
How were Stoke Therapeutics Inc’s earnings last quarter?
Stoke Therapeutics Inc released its earnings results on Nov 04, 2025. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.568 by -$0.082.
Is Stoke Therapeutics Inc overvalued?
According to Wall Street analysts Stoke Therapeutics Inc’s price is currently Undervalued.
Does Stoke Therapeutics Inc pay dividends?
Stoke Therapeutics Inc does not currently pay dividends.
What is Stoke Therapeutics Inc’s EPS estimate?
Stoke Therapeutics Inc’s EPS estimate is -0.73.
How many shares outstanding does Stoke Therapeutics Inc have?
Stoke Therapeutics Inc has 57,117,150 shares outstanding.
What happened to Stoke Therapeutics Inc’s price movement after its last earnings report?
Stoke Therapeutics Inc reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.568. Following the earnings report the stock price went down -9.945%.
Which hedge fund is a major shareholder of Stoke Therapeutics Inc?
Currently, no hedge funds are holding shares in STOK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stoke Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.75 (15.43% Upside)
$35.75 (15.43% Upside)
Blogger Sentiment
Bullish
STOK Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 58.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
256.79%
12-Months-Change
Fundamentals
Return on Equity
15.02%
Trailing 12-Months
Asset Growth
22.82%
Trailing 12-Months
Company Description
Stoke Therapeutics Inc
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
STOK Company Deck
STOK Earnings Call
Q3 2025
0:00 / 0:00
STOK Stock 12 Month Forecast
Average Price Target
$35.75
▲(15.43% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Xeris Pharmaceuticals
―
CureVac
―
Rapport Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---